Singapore, May 21 -- Accro Bioscience Inc., a China-based clinical-stage biotechnology startup pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases, has announced the closing of its $50 million Series C financing.

The round was led by OrbiMed, with participation from TCG Crossover (TCGX), LAV, Cenova Capital, and existing investors Shenzhen Capital Group ("SCGC") and Oriza Holdings.

Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&I diseases.

Dr Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, sai...